SBI-183
SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM) . SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo [1].
Product Specifications
CAS Number
625403-59-0
UNSPSC
12352005
Target
Transmembrane Glycoprotein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sbi-183.html
Purity
99.8
Smiles
O=C(C1=CC(OC)=CC=C1)NC2=CC=C(N3CCCC3)C=C2
Molecular Formula
C18H20N2O2
Molecular Weight
296.36
References & Citations
[1]Fifield, et al. Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular cancer therapeutics. 2020, 19 (1), 112–122.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Syndecan-1 Monoclonal Antibody, PerCP Conjugated
VN1R89P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
ARL3, NT (ADP-ribosylation Factor-like Protein 3, ARFL3) (MaxLight 750) discontinued
